Northern Trust
RSLS

Northern Trust’s ReShape Lifesciences Inc. Common Stock RSLS Stock Holding History

Northern Trust’s Portfolio RSLS Stock Details RSLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-9
Closed -$27K – 4350
2018
Q1 		$27K Buy
+9
New +$28.6K ﹤0.01% 4145

Other funds holding RSLS

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
RWP
RWA Wealth Partners Newton, Massachusetts $9.14B AUM 16.57% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust's RSLS Position: Q2 2018 in Review

Northern Trust sold out of ReShape Lifesciences Inc. Common Stock (RSLS) in Q2 2018, closing a stake of 9 shares — an estimated $27K sold.

Northern Trust first reported a position in RSLS in Q1 2018 and held it in 1 quarter. The position peaked at $27K in Q1 2018. 11 funds tracked by Wall St. Rank hold RSLS as of Q2 2018.

  • Northern Trust reported no remaining ReShape Lifesciences Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Northern Trust sold 9 ReShape Lifesciences Inc. Common Stock shares in Q2 2018, an estimated $27K.
  • Northern Trust first reported a position in ReShape Lifesciences Inc. Common Stock in Q1 2018 and held it in 1 quarter.
  • Northern Trust's ReShape Lifesciences Inc. Common Stock position peaked at $27K in Q1 2018.
  • 11 funds tracked by Wall St. Rank held ReShape Lifesciences Inc. Common Stock as of Q2 2018.

Based on Northern Trust's 13F filing for Q2 2018, filed 14 Aug 2018.